Scientific and Framework History

BAT Levels Timeline: From Alzheimer’s Biomarkers to the BATWatch Framework

Understanding modern brain biomarker monitoring requires looking at the discoveries that made it possible.

For more than a century, researchers have studied the biological signals associated with Alzheimer's disease and related neurodegenerative processes. Advances in pathology, molecular biology, and biomarker measurement gradually changed how scientists observe brain health long before symptoms appear.

The timeline below highlights key milestones in that scientific progression - from the earliest pathological descriptions of Alzheimer's disease to plasma biomarkers and longitudinal monitoring approaches.

It also shows how BATWatch organized existing literature into a terminology and monitoring framework designed to support clearer discussion of biomarker trends over time.

Each milestone connects to source material that forms part of the BATWatch Evidence Matrix.

Era 1: Scientific Discovery (1906-2010)

  1. 1906

    First Alzheimer pathology case is documented

    Alois Alzheimer described progressive cognitive decline with plaque and tangle pathology, creating the disease-model context later used in biomarker research.

    Historical portrait of Alois Alzheimer.
    Figure: Alois Alzheimer, whose 1906 case description first documented the plaque and tangle pathology associated with Alzheimer's disease.

    Reference: Hippius H, Neundorfer G, Dialogues in Clinical Neuroscience, 2003 (PMID: 22034141)

  2. 1984

    Beta-amyloid plaque core protein is characterized

    Biochemical isolation of beta-amyloid from plaque material established a measurable molecular target for future assay development.

    Reference: Glenner GG, Wong CW, Biochemical and Biophysical Research Communications, 1984 (DOI: 10.1016/S0006-291X(84)80190-4)

  3. 1995

    CSF tau staging becomes a biomarker milestone

    CSF tau findings strengthened evidence that tau can be measured as a biological signal, supporting later multi-marker panel models.

    Reference: Blennow K et al., European Archives of Psychiatry and Clinical Neuroscience, 1995 (DOI: 10.1007/BF02815140)

  4. 2001-2005

    Aβ42/40, tau panels, and amyloid PET advance in parallel

    Clinical assay refinement and early amyloid PET studies improved in vivo and fluid-based signal interpretation, making longitudinal biomarker comparisons more practical.

    Reference: Blennow K et al., Molecular Neurobiology, 2001 (DOI: 10.1385/MN:24:1-3:087)

  5. 2006-2010

    Multicenter standardization improves comparability

    Cross-site biomarker protocol work reduced interpretation variability and supported broader use of biomarker frameworks in research and translational settings.

    Reference: De Meyer G et al., Archives of Neurology, 2010 (DOI: 10.1001/archneurol.2010.179)

Era 2: Biomarker Translation Era (2011-2020)

  1. 2011-2015

    Preclinical biomarker frameworks are formalized

    Research criteria and framework papers integrated amyloid and tau biomarkers into staged models, linking molecular patterns with earlier monitoring windows.

    Portrait of Reisa Sperling.
    Figure: Reisa Sperling, whose work helped establish biomarker-based staging frameworks for preclinical Alzheimer's disease.

    Reference: Sperling RA et al., Neuron, 2011 (PMID: 21514248)

  2. 2016-2020

    Plasma assays become clinically usable at scale

    Ultra-sensitive blood assays for Aβ42/40 and pTau advanced across multicenter cohorts, supporting noninvasive, repeatable measurement for trend-based follow-up.

    Reference: Schindler SE et al., Neurology, 2019 (DOI: 10.1212/WNL.0000000000008081)

Era 3: BATWatch Framework Era (2021-Present)

  1. 2022

    BAT terminology framework is introduced

    BAT Levels, BAT Testing, and BATWatch terminology were organized into a consistent language layer used for education, reporting, and cross-page knowledge mapping.

    Reference: BATWatch terminology glossary context, BatLevels.org, 2026 (Glossary and term definitions)

  2. 2023

    BAT Testing workflow is documented as assay-agnostic monitoring

    The framework was structured around repeat blood measurement and trend interpretation rather than reliance on any single vendor assay.

    Reference: BAT Testing framework documentation, BatLevels.org, 2026 (BAT Testing article cluster)

  3. 2024

    BATCheck and BATScore reporting layers are standardized

    Snapshot and Complete pathways were formalized to support provider-guided interpretation of longitudinal biomarker context with consistent report structure.

    Reference: BATCheck reporting framework context, BatLevels.org, 2026 (BATCheck article cluster)

  4. 2025

    Observational registry and education layers are expanded

    BATWatch registry documentation and TeamBrain educational pathways were used to support observational trend learning and public-facing normalization of repeat monitoring language.

    Reference: BATWatch registry and education context, BatLevels.org, 2026 (BATWatch registry context)

  5. Present Day

    Longitudinal biomarker monitoring continues to evolve

    Plasma assays, interpretation frameworks, and observational registries continue expanding the ability to study brain health trends across populations over time.

    Conceptual progression model for longitudinal biomarker trend development over time.
    Illustrative longitudinal biomarker progression model used in BATWatch terminology discussions for describing biological trend development over time.

    Reference: BAT Testing Matrix and research index context, BatLevels.org, 2026 (BAT Testing Matrix)

Related Pages

BAT Testing Matrix

Representative citation scan by period with direct source links.

BATReset Matrix

Management-side evidence context for mTOR/autophagy discussion.

Research Links

Repository and DOI destinations used across BATwiki.